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Editorial on the Research Topic
Genetics of Paroxysmal Movement Disorders
Paroxysmal movement disorders represent a heterogeneous group of rare neurological conditions,
characterized by episodic and transient occurrence of hyperkinetic movements, such as chorea,
dystonia, ballism, and/or ataxia, and usually normal interictal examination. These may be
classified according to triggering factors, pathophysiological mechanisms, and genetic causes.
In the last decades, the progress of molecular genetics has improved our knowledge of
the paroxysmal dyskinesias (PxD) etiology, providing further advances in understanding the
underlying pathophysiology and definition of different clinical syndromes (1, 2). High-throughput
sequencing techniques like Next Generations Sequencing (NGS) have allowed us to identify several
monogenic forms of PxD and a number of loci and variants playing a role in mild to strong risk
factors. Genetic heterogeneity is often associated with clinical variability and complex phenotypes,
leading to a significant diagnostic delay. Therefore, most neurologists are still unable to recognize
these rare and complex disorders, which are often misclassified as epileptic or functional conditions
and not properly and promptly treated. Furthermore, the accurate identification of these disorders
is necessary for a correct family counseling.
The present Research Topic focuses on a modern revision of the last genetic discoveries in the
PxD area, including four articles and four reviews aiming to advance some of the research issues
that still need to be addressed.
Harvey et al. conducted an updated overview on PxD genetics based on a modern classification
and reorganization, according to the underlying pathophysiologic mechanism and involved
genes. Interestingly, the authors devised a detailed and useful table containing data concerning
inheritance, phenotypic manifestations, association with epilepsy, and recommended therapeutic
strategies for each gene. They proposed a diagnostic genetic algorithm suggesting which the first-
and second-tier tests are and discussed the advantages and limitations of the latest generation
techniques such as whole-exome and whole-genome sequencing.
In their review, Danti et al. dealt with the clinical, genetic, pathophysiological, and therapeutic
features of paroxysmal exercise-induced syndromes occurring in childhood, focusing, in particular,
on the different etiologies. The authors discussed other pediatric neurological conditions triggered
by physical activity or exercise, such as myalgia, cramping, rhabdomyolysis, myotonia, stiffness,
and weakness due to neurometabolic, neuromuscular, neurodegenerative, and epileptic disorders.
Furthermore, they underlined the possible psychogenic etiology of these disorders, which is rarely
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described and recognized in childhood. Finally, the review
provides a detailed diagnostic algorithm including imaging tools,
metabolic and biochemical screening, and genetic testing.
Paroxysmal kinesigenic dyskinesia (PKD) is usually caused
by PRRT2 gene mutations. In their timely review, Landolfi
et al. dissected the variations of the core phenotype of PKD
and epilepsy due to PRRT2 mutations and discussed rarer
associations like paroxysmal hypnogenic dyskinesias, episodic
ataxia, or hemiplegic migraine. They also examine the molecular
and neurophysiological effects of PRRT2 mutations and how
the pathophysiological insights lead to the evolving concept
of synaptopathies.
Four articles and one mini review included in this issue
are focused on expanding the phenotypes and exploring the
genotype-phenotype correlations of other genes variants more
rarely involved in the PxD pathogenesis.
Yang et al. reported 11 patients presenting with epilepsy and
developmental delay, and carrying likely pathogenic GNAO1
gene variants, 6 of whom to be considered novel. Five cases
complained of paroxysmal brief focal or truncal dystonia
triggered by sound stimulus or emotional disturbances.
Kegele et al. reported two novel pathogenic variants inKCNA1
gene, encoding a potassium channel subunit, in one case of PKD
and one of non-kinesigenic dyskinesia, respectively. KCNA1 gene
mutations usually account for other paroxysmal neurological
conditions as episodic ataxia type 1 (EA1), epilepsy, and other
rare disorders, as isolated neuromyotonia, myokymia, and
hypomagnesemia (3). The authors confirmed the heterogeneity
of KCNA1-related phenotypes and proposed acetazolamide as
first-line (in analogy with EA1) or alternative treatment to
sodium channel blockers in resistant PxD patients. Furthermore,
Kegele et al. also described exercise-induced dyskinesia in other
two patients carrying likely pathogenic SLC2A1 gene variants,
one of which was described for the first time. Both cases also
showed other clinical features that are usually observed inGLUT1
syndrome, such as epilepsy, and/or psychomotor slowing, and/or
hemiplegic migraine.
One of the phenotypes of KCNA1 gene, EA1, is clinically
characterized by attacks lasting seconds to minutes with variable
symptoms and persistent myokymia (Lauxmann et al.). There
is no standardized treatment approach; some patients are
treated with acetazolamide, others with sodium channel blockers.
Lauxman et al. reviewed this condition, used a predictive
scoring system to evaluate the effects of mutations on neuronal
excitability, and assessed the effects of sodium channel blockers.
They found that phenytoin, carbamazepine, and riluzole may
partly ameliorate the detrimental effects on channel function,
supporting their use as “targeted therapies” for this condition.
CACNA1A gene mutations were first found to cause both
familial hemiplegic migraine and episodic ataxia type 2 (4).
Later, a CAG repeat expansion in CACNA1A was found
to be the cause of SCA6 (5). Since then, our knowledge
of CACNA1A-related disorders has rapidly expanded, as
highlighted by a concise and topical review by Indelicato and
Boesch. Age-dependent phenotypes are described including
neuropsychiatric disorders, paroxysmal dystonia, epilepsy, and
complex phenotypes combining early developmental delay and
epileptic encephalopathy. Additionally, the authors reviewed
the underlying pathophysiology and treatment implications and
provided recommendations on genetic testing for CACNA1A.
Another rare paroxysmal movement disorder is represented
by the alternating hemiplegia (AHC) of childhood, which
is characterized by onset in infancy or early childhood of
episodes of hemiplegia on either side and other paroxysmal
manifestations such as dystonia, quadriparesis, seizure-like
episodes, oculomotor abnormalities, and autonomic dysfunction
(6). Previous studies have suggested that 85% of cases are due
to heterozygous mutations in the ATP1A3 gene (7). In a study
of AHC, Cordani et al. recruited 39 patients and detected
ATP1A3 gene mutations in a higher than expected 92.3% of
cases. Furthermore, they also conducted a genotype-phenotype
correlation analysis.
In conclusion, this Research Topic aims to reorganize the
knowledge derived from NGS technique application to PxD,
emphasizing the broad clinical variability, the intersection
between different phenotypes, and, finally, the importance of
correctly interpreting genetic testing results. The issue also
attempts to provide algorithms for identification and diagnosis,
and suggests possible therapeutic strategies.
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